EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes

Junliang Zhao iD, Yuanwei Li iD, Xinyang Cai iD, Diwei Zhao, Jun Wang, Xingbo Long, Yijun Zhang iD, Yun Cao, Dong Chen, Fangjian Zhou, Zhenyu Yang iD, Yonghong Li iD

The Prostate · 2026-12 · 86 (16) · 1645-1652

DOI: 10.1002/pros.70250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 19.09.2026. Verfasst von Junliang Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen Univers…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Neoadjuvant Therapy, Prostate-Specific Antigen. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China., Basic and Applied Basic Research Foundation of Guangdong Province., National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the impact of neoadjuvant hormonal therapy (Neo‐HT) on postoperative pathological and prostate‐specific antigen (PSA) outcomes after radical prostatectomy (RP) and oncological outcomes in patients with favorable postoperative outcomes (pT0‐2N0, negative surgical margin and undetectable PSA).

Methods

A total of 1099 prostate cancer (PCa) patients who underwent RP were divided into the direct RP group or the Neo‐RP group (Neo‐HT before RP). We compared the proportions achieving favorable postoperative outcomes. Oncological endpoints included biochemical progression‐free survival (bPFS), local recurrence‐free survival (LRFS), and metastasis‐free survival (MFS). Predictors of biochemical recurrence (BCR) were identified using multivariable Cox regression. Propensity score matching (PSM) was applied to balance baseline characteristics.

Results

Neo‐HT increased the proportions achieving favorable postoperative outcomes among both low‐to‐intermediate and high‐risk patients (42.02% vs. 23.63%, p < 0.001). Among 362 patients with favorable postoperative outcomes, unadjusted 3‐year bPFS was worse in the Neo‐RP group (81.5% vs. 93.6%, p = 0.008), with similar patterns for LRFS and MFS. Baseline PSA > 20 ng/ml, Gleason score 8–10, and cT2c‐4 were independent predictors of BCR, and no statistically significant differences in bPFS, LRFS, or MFS were observed in the PSM cohort.

Conclusions

Neo‐HT enables more PCa patients to achieve favorable postoperative outcomes. Among patients with favorable postoperative outcomes, those with high‐risk baseline features are more likely to experience BCR irrespective of Neo‐HT. The apparent improvements in postoperative pathological and PSA outcomes after Neo‐HT may obscure recurrence risk, underscoring the need to incorporate baseline characteristics into postoperative risk stratification and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyNeoadjuvant TherapyProstate-Specific AntigenAntineoplastic Agents, HormonalMaleHumansMiddle AgedTreatment OutcomeAgedNeoplasm Recurrence, LocalRetrospective Studies

Stichwörter der Autor:innen

biochemical recurrenceneoadjuvant hormonal therapyradical prostatectomy

Substanzen

Prostate-Specific AntigenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

ORCID-Profile: Junliang Zhao, Yuanwei Li, Xinyang Cai, Yijun Zhang, Zhenyu Yang, Yonghong Li

Förderung

  • National Natural Science Foundation of China.
  • Basic and Applied Basic Research Foundation of Guangdong Province.
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, J., Li, Y., Cai, X., Zhao, D., Wang, J., Long, X., Zhang, Y., Cao, Y., Chen, D., Zhou, F., Yang, Z., & Li, Y. (2026). Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes. The Prostate, 86(16), 1645-1652. https://doi.org/10.1002/pros.70250

Vancouver

Zhao J, Li Y, Cai X, Zhao D, Wang J, Long X, et al. Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes. The Prostate. 2026;86(16):1645-1652. doi:10.1002/pros.70250

BibTeX
@article{Zhao2026,
  author = {Zhao, Junliang and Li, Yuanwei and Cai, Xinyang and Zhao, Diwei and Wang, Jun and Long, Xingbo and Zhang, Yijun and Cao, Yun and Chen, Dong and Zhou, Fangjian and Yang, Zhenyu and Li, Yonghong},
  title = {Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {16},
  pages = {1645--1652},
  doi = {10.1002/pros.70250}
}
Kostenlos starten →